RedHill Wins Two More U.S. Patents on Gastrointestinal Therapy BEKINDA

RedHill Wins Two More U.S. Patents on Gastrointestinal Therapy BEKINDA
RedHill Biopharma has received two more U.S. patents for its gastrointestinal therapy BEKINDA (ondansetron). The patents cover RedHill’s propriety formulation of its extended-release ondansetron tablet, and the way BEKINDA is used in treatment. “We are very pleased with the allowance of two additional U.S. patents for BEKINDA,” Danielle Abramson, RedHill’s director of intellectual property and research, said

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *